33 results about "Promoter enhancer" patented technology

This invention provides a method for treating a subject afflicted with a tumor using genetically modified mesenchymal stem cells, wherein each genetically modified mesenchymal stem cell contains an exogenous nucleic acid comprising (i) a cytotoxic protein-encoding region operably linked to (ii) a promoter or promoter / enhancer combination, whereby the cytotoxic protein is selectively expressed when the genetically modified mesenchymal stem cells come into proximity with the tumor's stromal tissue. This invention further provides genetically modified mesenchymal stem cells for use in this method.

The invention provides methods and compositions for assembling a modular replacement genome in a host microorganism. After such assembly, the host organism's genome is inactivated or ablated to permit full control of host cellular functions by the replacement genome. A modular replacement genome comprises an assembly of nucleic acid fragments, or segments, derived from one or more natural organisms or from synthetic polynucleotides or from a combination of both. Such an assembly, or set, of segments making up a replacement genome comprises a substantially complete set of genes and regulatory elements for carrying out minimal life functions under predefined culture conditions. The invention provides modular genomes having modules that are amenable to facile replacement, deletion, and / or additions. Such modules may be synthetic polynucleotides and may be designed for controlling gene content, excluding of genes that encode inhibitors or otherwise undesirable competing enzymes that divert a host cell from desired metabolic / synthetic processes; modifying codon usage to maximize or minimize protein production; modifying regulatory elements, including promoters, enhancers, repressors, activator, or the like, to modulate gene expression; balancing enzymatic and transport activities to optimize fluxes of substrates, intermediates, and products in metabolic pathways, and like objectives.

Provided is an expression vector for gene therapy. The expression vector comprises a new combination which contains a transcriptional control element and comprises a promoter, an enhancer, an intron, an untranslated region (UTR) and a loca control region (LCP). The expression vector can continuously express specific genes of hepatic tissue so that the expression vector can be effectively used in treating thrombus forming, hemophilia, liver cancer and the like.

The invention relates to a lentivirus packaging vector system, a lentivirus, a construction method thereof, and a kit. The lentiviral packaging vector system consists of two or more plasmids, which can produce lentiviruses with only one infection ability but no replication ability. One of the plasmids contains sequentially linked promoters, enhancers, and encoding envelope proteins A nucleic acid fragment, the nucleic acid fragment encoding the envelope protein comprises a nucleic acid fragment for expressing the S protein of SARS-CoV-2 or a nucleic acid fragment for expressing a mutant of the S protein of SARS-CoV-2, for expressing SARS-CoV-2 The mutant of the S protein of CoV-2 is that the 614th amino acid at the C-terminus of the S1 subunit of the S protein of SARS-CoV-2 is mutated from aspartic acid to glycine. The lentivirus prepared by the above-mentioned lentiviral packaging vector system can be used to screen drugs against SARS-CoV-2 or its mutant strains, and has high safety.